CLAIMS:

1. A composition suitable for delivery onto oral and/or nasal mucosa, the composition comprises at least one sulfated polysaccharide polymer and at least one hydrophobic or hydrophilic polymer that are partially crosslinked by at least one positively charged ion to a degree of crosslinking (DC) in the range of at least about 1 to 5 percent,

wherein the composition is in a liquid, a semiliquid or sprayable form, and

wherein the composition has a substantially constant viscosity at room temperature (RT), as measured by a rheometer under varying shear forces and having less than 25% deviation for varying shear rates in the range between about 0.1 and about 10 s^{-1},

such that contacting the oral and/or nasal mucosa with the composition, it transforms into a uniform and continuous film.

2. The composition of claim 1, wherein the DC in the range of at least about 5 to 10, 20 to 30, 30-40 or 40-50 percent.

3. The composition of claim **1** or **2**, comprising micro or nanoparticles or droplets.

4. The composition of claim **1** or **2**, wherein the at least one sulfated polysaccharide polymer and the at least one hydrophobic or hydrophilic polymer are synthetic, semisynthetic, natural polymers obtained from a plant, an animal or a microbial origin or modified natural polymers, or any combination thereof.

5. The composition of claim **1** or **2**, wherein the at least one sulfated polysaccharide polymer is selected from sulfated galactans, ulvans, fucan, fucoidans, heparins, glucosamines, dextrans, chitosan, chitin and chondroitin.

6. The composition of claim **1** or **2**, wherein the at least one sulfated polysaccharide polymer is at least one carrageenan selected from iota carrageenan, kappa carrageenan and lambda carrageenan.

7. The composition of claim **1** or **2**, wherein the at least one hydrophobic or hydrophilic polymer is a hydrophilic polymer which is a polysaccharide or a protein.

8. The composition of claim **7**, wherein the polysaccharide is selected from dextrans, alginates, chitosans, agaroses and pullulans.

9. The composition of claim **7**, wherein the protein is selected from albumins, gelatins, collagens, lectins, legumines, and vicilines.

10. The composition of claim **1** or **2**, wherein the at least one hydrophobic or hydrophilic polymer is a hydrophilic polymer which is alginate or an alginate salt.

11. The composition of claim **1** or **2**, wherein the at least one positively charged ion is a di-valent cation selected from Ba^{2+}, Be^{2+}, Ca^{2+}, Co^{2+}, Mg^{2+}, Cu^{2+}, Ni^{2+}, Fe^{2+} and Zn^{2+}.

12. The composition of claim **1** or **2**, wherein the at least one sulfated polysaccharide polymer is a carrageenan and the at least one hydrophilic polymer is an alginate and the at least one positively charged ion is Ca^{2+}.

13. The composition of claim **12**, wherein the carrageenan is at a concentration in a range between about 0.005% and about 1%, the alginate is at a concentration in a range between about 0.1% and about 3%, and the Ca^{2+} is at a concentration in a range between about 0.0001% and about 1% (w/w).

14. The composition of any one of the preceding claims, further comprising at least one additional therapeutic agent.

15. A pharmaceutical composition comprising a therapeutically effective amount of the composition of any one of claims **1** to **14** and a pharmaceutically acceptable buffer, carrier or excipient.

16. The pharmaceutical composition of claim **15**, which is adapted for oral and/or nasal administering in the form of a spray or a gel, or oral and/or nasal inhalation in the form of particles or droplets.

17. The composition of any one of claims **1** to **14** for use in protecting oral and/or nasal mucosal barrier function.

18. The composition of any one of claims **1** to **14** for use in preventing, alleviating or treating a disorder or a condition related to oral and/or nasal mucosal barrier dysfunction.

19. A composition suitable for delivery onto oral and/or nasal mucosa, the composition comprises at least one sulfated polysaccharide polymer and at least one hydrophilic polymer that are partially crosslinked by at least one positively charged ion,

wherein the composition is in a liquid, a semiliquid or sprayable form,

wherein the at least one sulfated polysaccharide polymer is a carrageenan and the at least one hydrophilic polymer is an alginate and the at least one positively charged ion is Ca^{2+} provided at the concentrations of about 0.005% to about 1%, about 0.1% to about 3% and about 0.0001% to about 1% (w/w), respectively, and

wherein the composition has a substantially constant viscosity at room temperature (RT), as measured by a rheometer under varying shear forces and having

less than 25% deviation for varying shear rates in the range between about 0.1 and about 10 s^{-1},

such that contacting the oral and/or nasal mucosa with the composition, it transforms into a uniform and continuous film.

20. Use of the composition of any one of claims **1** to **14** in the manufacture of a medicament for preventing, alleviating or treating an aeroallergen induced allergy and/or inflammation.

21. Use of the composition of any one of claims **1** to **14** in the manufacture of a medicament for preventing, alleviating or treating a microbial oral and/or nasal infection.